ICD-10-CM Codes | Explanation of Codes |
D06._ | Carcinoma in situ of the cervix |
D13.7 | Benign neoplasm of endocrine pancreas Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2- Islet cell adenoma
- Nesidioblastoma
- Islet cell adenomatosis
- Insulinoma
- Beta cell adenoma
|
D21.4 | Benign neoplasm of connective and other soft tissue of abdomen Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2 Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3) |
D23.9 | Other benign neoplasm of skin Benign carcinoid tumors of other sites Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2- Aggressive digital papillary adenoma (C44_) (8408/1, but now 8408/3)
|
D35.0_ | Benign neoplasm of adrenal gland Note: Effective 1/1/2021: Review this code to look for the following which was previously a benign (8700/0) tumor of the adrenal gland, but is now malignant per ICD-O-3.2 (8700/3)- Pheochromocytoma
- Adrenal medullary paraganglioma
- Chromaffin paraganglioma
- Chromaffin tumor
- Chromaffinoma
|
D37.8 | Neoplasm of uncertain behavior of other specified digestive organs (includes uncertain behavior of pancreas) Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2- Pancreatic endocrine tumor, NOS (C259, 8150/1, now 8150/3)
- Islet cell tumor, NOS (C259, 8150/1, now 8150/3)
- Glucagonoma, NOS (C259, 8152/1, now 8152/3)
- Alpha cell tumor, NOS (C259, 8152/1, now 8152/3)
- Glucagon-like peptid-producing tumor (C259, 8152/1, now 8152/3)
- Somastostatinoma, NOS (8156/1, now 8156/3)
- Endocrine tumor, functioning, NOS (8158/1/, now 8158/3)
ACTH-producing tumor (8158/1, now 8158/3) |
D3A._ | Benign carcinoid tumors Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign or borderline tumors, but are now malignant per ICD-O-3.2- Carcinoid tumor, argentaffinoma, NOS (8240/1, now 8241/3)
- Enterochromaffin-like cell carcinoid, NOS (8242/1, now 8241/3)
|
D44.6 | Neoplasm of uncertain behavior of carotid body Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2- Carotid body tumor/Carotid body paraganglioma (8962/1, now 8962/3)
|
D44.7 | Neoplasm of uncertain behavior of aortic body and other paraganglia Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2- Paraganglioma, NOS (8680/1, now 8680/3)
- Sympathetic paraganglioma (8681/1, now 8681/3)
- Parasympathetic paraganglioma (8682/1, now 8682/3)
- Glomulus jugulare tumor, NOS/jugular paraganglioma/juglotympanic paraganglioma (8690/1, now 8690/3)
- Aortic body tumor/aortic body paraganglioma/aorticopulmonary paraganglioma (8691/1, now 8691/3)
- Extra-adrenal paraganglioma, NOS/nonchromaffin paraganglioma, NOS/chemodectroma (8693/1, now 8693/3)
|
D48.0 | Neoplasm of uncertain behavior of bone and articular cartilage Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2- Clear cell odontogenic tumor (9341/1, now 9341/3)
|
D48.1 | Neoplasm of uncertain behavior of connective and other soft tissue of abdomen Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2 Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3) |
D49.2 | Neoplasm of unspecified behavior of digestive organs (includes unspecified behavior of pancreas) Note: Review this code to look for the following which were previously unknown behavior tumors of the pancreas, but are now malignant tumors per ICD-O-2.3 (Histology 8150/3)- Pancreatic endocrine tumor, NOS
- Islet cell tumor, NOS
|
D61.810 | Antineoplastic chemotherapy induced pancytopenia |
D64.81 | Anemia due to antineoplastic chemotherapy |
D70.1 | Agranulocytosis secondary to cancer chemotherapy |
D72.10 | Eosinophilia, NOS (Note: Screen for incorrectly coded Chronic eosinophilic leukemia, 9964/3) |
D75.81 | Myelofibrosis (note: this is not primary myelofibrosis [9961/3]) |
E31.2_ | Multiple endocrine neoplasia [MEN] syndromes |
E34.0 | Carcinoid syndrome |
E88.3 | Tumor lysis syndrome (following antineoplastic chemotherapy) |
G89.3 | Neoplasm related pain (acute)(chronic) |
H47.42 | Disorders of optic chiasms in (due to) neoplasm |
H47.52_ | Disorders of visual pathways in (due to) neoplasm |
H47.63_ | Disorders of visual cortex in (due to) neoplasm |
I31.31 | Malignant pericardial effusion in diseases classified elsewhere |
J70.0 | Acute pulmonary manifestations due to radiation |
J70.1 | Chronic and other pulmonary manifestations due to radiation |
J91.0 | Malignant pleural effusion |
K12.31 | Oral mucositis (ulcerative) due to antineoplastic therapy |
K12.33 | Oral mucositis (ulcerative) due to radiation |
K52.0 | Gastroenteritis and colitis due to radiation |
K62.7 | Radiation proctitis |
K62.82 | Dysplasia of anus (AIN I and AIN II) |
K92.81 | Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy) |
L58._ | Radiodermatitis |
L59.8 | Other disorders of skin and subcutaneous tissue related to radiation |
L59.9 | Disorder of the skin and subcutaneous tissue related to radiation, unspecified |
M31.11 | Hematopoietic stem cell transplantation-associated thrombotic microangioplasty |
M96.2 | Postradiation kyphosis |
M96.5 | Postradiation scoliosis |
N30.4_ | Irradiation cystitis |
N46.024 | Azoospermia due to radiation |
N46.124 | Oligospermia due to radiation |
N52.31-N52.32, N52.34-N52.36 | Post procedural erectile dysfunction (due to prostatectomy, cystectomy, radiation) |
O35.6_ | Maternal care for (suspected) damage to fetus by radiation |
O9A.1_ | Malignant neoplasm complicating pregnancy, childbirth and the puerperium |
P04.11 | Newborn affected by maternal antineoplastic chemotherapy |
P04.12 | Newborn affected by maternal cytotoxic drugs |
Q85.0_ | Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable |
R18.0 | Malignant ascites |
R53.0 | Neoplastic (malignant) related fatigue |
R97.21 | Rising PSA following treatment for malignant neoplasm of prostate |
T38.6_ | Poisoning by antigonadotropins, antiestrogens, antiandrogens, not elsewhere classified |
T38.8_, T38.9_ | Poisoning by hormones and their synthetic substitutes |
T45.1_ | Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs |
T45.8_, T45.9_ | Poisoning by primary systemic and hematological agent, unspecified |
T66._ | Unspecified effects of radiation |
T80.81_ | Extravasation of vesicant agent |
T80.82_ | Complication of immune effector cellular therapy
- Complication of chimeric antigen receptor (CAR-T) cell therapy
|
T86.0_ | Complications of bone marrow transplant |
Y63.2 | Overdose of radiation given during therapy |
Y84.2 | Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure |
Z08 | Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment) |
Z40.0_ | Encounter for prophylactic surgery for risk factors related to malignant neoplasms |
Z42.1 | Encounter for breast reconstruction following mastectomy |
Z48.290 | Encounter for aftercare following bone marrow transplant |
Z48.3 | Aftercare following care for neoplasm |
Z51.0 | Encounter for antineoplastic radiation therapy |
Z51.1_ | Encounter for antineoplastic chemotherapy and immunotherapy |
Z51.5, Z51.89 | Encounter for palliative care and other specified aftercare |
Z79.63_ | Long term (current) use of chemotherapeutic agent |
Z79.64 | Long term (current) use of myelosuppressive agent (hydroxyurea) |
Z79.81_ | Long term (current) use of agents affecting estrogen receptors and estrogen levels |
Z85._ | Personal history of malignant neoplasm |
Z86.00_ | Personal history of in situ neoplasm |
Z86.010 | Personal history of colonic polyps |
Z86.011 | Personal history of benign neoplasm of the brain |
Z86.012 | Personal history of benign carcinoid tumor |
Z92.21, Z92.23, Z92.25, Z92.3 | Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation) |
Z92.850 | Personal history of Chimeric Antigen Receptor T-cell therapy
- Personal history of CAR-T-cell therapy
|
Z94.81, Z94.84 | Bone marrow and stem cell transplant status |